Adj Assoc Prof Madelynn Chan Tsu-Li

DSRB Chairperson
National Healthcare Group

Senior Consultant Rheumatologist
Rheumatology, Allergy & Immunology
Tan Tock Seng Hospital

Madelynn Chan is Adjunct Associate Professor at NTU Lee Kong Chian School of Medicine and Senior Consultant Rheumatologist at the Department of Rheumatology, Allergy & Immunology, Tan Tock Seng Hospital. She is also a Chairperson with NHG DSRB.

Dr Chan graduated from the University of Western Australia and trained in rheumatology at Royal Perth Hospital in Western Australia and the Royal National Hospital for Rheumatic Diseases in Bath, England.  She was awarded her MD research thesis on SLE Serological Biomarkers at the University of Bath.

Dr Chan’s research interests include musculoskeletal health services and outcomes and systemic lupus erythematosus outcomes. She is a site investigator for randomized controlled clinical trials at TTSH and has experience with trials in rheumatoid and psoriatic arthritis, ankylosing spondylitis and systemic lupus erythematosus.

Panel Discussion

Emerging COVID-19 Hot Topic: Special Review for COVID-19

The COVID-19 pandemic is an unprecedented global challenge requiring intensive commitment of healthcare resources, public health interventions, private investment and geopolitical coordination. A central pillar to combatting the pandemic has been rapid research and development into diagnostic, therapeutic and prophylactic tools for COVID-19. This urgency has not meant that ethical standards for research should fall or be set aside, but rather that the processes for ethical review of research must be accelerated and streamlined to whatever extent feasible.

In this context, healthcare institutions in Singapore adapted existing ethics review structures to create a new domain-specific IRB specifically to review COVID-19 related studies in a rapid manner. This panel discussion will summarize this special review process, reflecting on what was achieved, challenges emerged along the way, and lessons for the future of ethics review – both for potential global health emergencies, as well as more routine biomedical research.

< Back to Speakers' Information